# Factor XI LICA to Reduce Events Such as Heart Attack and Stroke in Patients Whose Kidneys Are no Longer Able to Work as They Should and Require Treatment to Filter Wastes From the Blood: Focus is on the Safety of BAY2976217 and the Way the Body Absorbs, Distributes and Removes the Study Drug

Study · id `cardio:ct-nct04534114` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04534114](<https://clinicaltrials.gov/study/NCT04534114>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04534114

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 307 participants.

## Technical summary

Registry record NCT04534114. Randomized; quadruple masking; primary purpose treatment. Start 2020-09-04 (actual); primary completion 2022-01-24 (actual). Results posted on 2023-07-03.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 307 participants (enrolled count; ClinicalTrials.gov record NCT04534114, source copy `cardio:ctgov-nct04534114-2023-07-03`, retrieved 2026-10-26)
- Started: 2020-09-04 (actual) (ClinicalTrials.gov record NCT04534114, source copy `cardio:ctgov-nct04534114-2023-07-03`, retrieved 2026-10-26)
- Primary completion: 2022-01-24 (actual) (ClinicalTrials.gov record NCT04534114, source copy `cardio:ctgov-nct04534114-2023-07-03`, retrieved 2026-10-26)
- Completion: 2022-05-12 (actual) (ClinicalTrials.gov record NCT04534114, source copy `cardio:ctgov-nct04534114-2023-07-03`, retrieved 2026-10-26)
- Results first posted: 2023-07-03 (ClinicalTrials.gov record NCT04534114, source copy `cardio:ctgov-nct04534114-2023-07-03`, retrieved 2026-10-26)
- Countries: United States; Belgium; Bulgaria; Canada; Czechia; Germany; Greece; Hungary; Japan; Latvia; Russia; South Korea; Spain; Taiwan; Ukraine (ClinicalTrials.gov record NCT04534114, source copy `cardio:ctgov-nct04534114-2023-07-03`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04534114-2023-07-03`, retrieved 2026-10-26)

## The registry's words

- Brief title: Factor XI LICA to Reduce Events Such as Heart Attack and Stroke in Patients Whose Kidneys Are no Longer Able to Work as They Should and Require Treatment to Filter Wastes From the Blood: Focus is on the Safety of BAY2976217 and the Way the Body Absorbs, Distributes and Removes the Study Drug
- Acronym: RE-THINc ESRD
- Condition: End Stage Renal Disease Requiring Hemodialysis
- Intervention (Drug): Fesomersen sodium (BAY2976217)
- Intervention (Drug): Placebo
- Lead sponsor: Bayer
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Bayer (`cardio:bayer`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: A Phase II randomized controlled trial evaluated antithrombotic treatment with fesomersen in patients with kidney failure on hemodialysis (`cardio:pubmed-38537676`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 19f69abeda6115efd242fa242f683e846b70536740d26923cc9ee95550235ce8
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
